Drugs

, Volume 68, Issue 16, pp 2345–2356

Bivalirudin

In Patients with Acute Coronary Syndromes Planned for Urgent or Early Intervention
Adis Drug Profile
  • 43 Downloads

Abstract

  • ▲ Bivalirudin is a 20-amino acid synthetic polypeptide that directly inhibits both fibrin-bound and soluble thrombin.

  • ▲ In a randomized, open-label, phase III study (ACUITY) in 13 819 patients with acute coronary syndromes (unstable angina or non-ST-segment elevation myocardial infarction) in whom urgent or early intervention was planned, both bivalirudin plus a glycoprotein (GP) IIb/IIIa inhibitor and bivalirudin alone were noninferior to heparin plus a GP IIb/IIIa inhibitor for the primary endpoint of composite ischaemia (myocardial infarction, unplanned revascularization or death from any cause) at 30 days.

  • ▲ The primary endpoint of major bleeding not related to coronary artery bypass graft surgery had occurred in significantly fewer recipients of bivalirudin alone than of heparin plus a GP IIb/IIIa inhibitor after 30 days. Bivalirudin plus a GP IIb/IIIa inhibitor was noninferior to the heparin regimen with regard to this bleeding event.

  • ▲ Bivalirudin alone was also associated with a significantly lower incidence of the primary net clinical outcome endpoint (composite ischaemia or major bleeding) after 30 days. Bivalirudin plus a GP IIb/IIIa inhibitor was noninferior to the heparin regimen with regard to this endpoint.

  • ▲ The findings of ACUITY at 1 year indicate that both bivalirudin plus a GP IIb/IIIa inhibitor and bivalirudin alone were as effective as heparin plus a GP IIb/IIIa inhibitor with regard to the long-term incidence of composite ischaemia and all-cause mortality.

References

  1. 1.
    Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007 Jul; 28(13): 1598–660PubMedCrossRefGoogle Scholar
  2. 2.
    Wiggins BS, Spinler S. Antiplatelet and antithrombin therapy for early management of acute coronary syndromes. J Pharmacy Practice 2004; 17(5): 347–69CrossRefGoogle Scholar
  3. 3.
    American Heart Association and American Stroke Association. Heart disease and stroke statistics: 2008 update at-a-glance [online]. Available from URL: http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008.final.pdf [Accessed 2008 Jun 3]
  4. 4.
    Ramanath VS, Eagle KA. Evidence-based medical therapy of patients with acute coronary syndromes. Am J Cardiovasc Drugs 2007; 7(2): 95–116PubMedCrossRefGoogle Scholar
  5. 5.
    Mehta SR, Cannon CP, Fox KAA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005 Jun 15; 293(23): 2908–17PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007 Aug 14; 50(7): e1–157PubMedCrossRefGoogle Scholar
  7. 7.
    Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003 Oct; 24(20): 1815–23PubMedCrossRefGoogle Scholar
  8. 8.
    Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004 Oct 6; 292(13): 1555–62PubMedCrossRefGoogle Scholar
  9. 9.
    Segev A, Strauss BH, Tan M, et al. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005 Oct; 150(4): 690–4PubMedCrossRefGoogle Scholar
  10. 10.
    Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004 Mar; 17(1): 105–25PubMedCrossRefGoogle Scholar
  11. 11.
    European Medicines Agency. Angiox: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/angiox/H-562-PIen.pdf [Accessed 2008 May 14]
  12. 12.
    US Food and Drug Administration. Angiomax®: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2005/020873s011lbl.pdf [Accessed 2008 Jun 20]
  13. 13.
    Moen MD, Keating GM, Wellington K. Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention. Drugs 2005; 65(13): 1869–91PubMedCrossRefGoogle Scholar
  14. 14.
    Carswell CI, Plosker GL. Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs 2002; 62(5): 841–70PubMedCrossRefGoogle Scholar
  15. 15.
    Bates ER. Bivalirudin: an anticoagulant option for percutaneous coronary intervention. Expert Rev Cardiovasc Ther 2004 Mar; 2(2): 153–62PubMedCrossRefGoogle Scholar
  16. 16.
    Nielsen VG, Steenwyk BL, Gurley WQ, et al. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 2006 Jun; 25(6): 653–63PubMedCrossRefGoogle Scholar
  17. 17.
    Tanaka KA, Szlam F, Sun HY, et al. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg 2007 Oct; 105(4): 933–9PubMedCrossRefGoogle Scholar
  18. 18.
    Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993 Feb 1; 69(2): 157–63PubMedGoogle Scholar
  19. 19.
    Lincoff AM, Bittl JA, Kleiman NS, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004 May 1; 93(9): 1092–6PubMedCrossRefGoogle Scholar
  20. 20.
    Robson R, White H, Aylward P, et al. Bivalirudin pharmaco-kinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002 Jun; 71(6): 433–9PubMedCrossRefGoogle Scholar
  21. 21.
    Kleiman NS, Klem J, Fernandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J 2002 Apr; 143(4): 585–93PubMedCrossRefGoogle Scholar
  22. 22.
    Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993 Apr 1; 71(10): 778–82PubMedCrossRefGoogle Scholar
  23. 23.
    Lidón R-M, Théroux P, Juneau M, et al. Initial experience with a direct antithrombin, hirulog, in unstable angina: anticoagulant, antithrombotic, and clinical effects. Circulation 1993 Oct; 88 (4 Pt 1): 1495–501PubMedCrossRefGoogle Scholar
  24. 24.
    Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007 Aug 1; 100(3): 417–24PubMedCrossRefGoogle Scholar
  25. 25.
    Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 2002 Jun; 13(3): 161–5PubMedCrossRefGoogle Scholar
  26. 26.
    Keating FK, Dauerman HL, Whitaker DA, et al. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118(3): 361–9PubMedCrossRefGoogle Scholar
  27. 27.
    Lev El, Patel R, Karim A, et al. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. Thromb Haemost 2006 Mar; 95(3): 441–6PubMedGoogle Scholar
  28. 28.
    Keating FK, Dauerman HL, Whitaker DA, et al. The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005 Sep1; 16(6): 401–5PubMedCrossRefGoogle Scholar
  29. 29.
    Irvin W, Sica D, Gehr T, et al. Pharmacodynamics (PD) and kinetics (PK) of bivalirudin (BIV) in renal failure (RF) and hemodialysis (HD) [abstract no. PIII-104]. Clin Pharmacol Ther 1999 Feb; 65(2): 202CrossRefGoogle Scholar
  30. 30.
    Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina: results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995 Aug 15; 92(4): 727–33PubMedCrossRefGoogle Scholar
  31. 31.
    Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. Am Heart J 2002 Feb; 143(2): 229–34PubMedCrossRefGoogle Scholar
  32. 32.
    Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006 Nov 23; 355(21): 2203–16PubMedCrossRefGoogle Scholar
  33. 33.
    Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007 Dec 5; 298(21): 2497–506PubMedCrossRefGoogle Scholar
  34. 34.
    Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. Lancet 2007 Mar 17; 369(9565): 907–19PubMedCrossRefGoogle Scholar
  35. 35.
    White HD, Chew DP, Hoekstra JW, et al. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008 May 6; 51(18): 1734–41PubMedCrossRefGoogle Scholar
  36. 36.
    Feit F, Manoukian SV, Ebrahimi R, et al. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008 Apr 29; 51(17): 1645–52PubMedCrossRefGoogle Scholar
  37. 37.
    White HD, Ohman M, Lincoff AM, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008 Sep 2; 52(10): 807–14PubMedCrossRefGoogle Scholar
  38. 38.
    European Medicines Agency. Angiox: scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/angiox/Angiox-AR-H-562-II-08.pdf [Accessed 2008 Jul 25]
  39. 39.
    Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 2004 Nov; 148(5): 764–75PubMedCrossRefGoogle Scholar
  40. 40.
    Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000 Aug 16; 284(7): 835–42PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore 0754, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations